Gritstone bio, Inc. Stock: price and insider trades · United States

The company’s corporate history is important for investors. It was originally incorporated as a Delaware corporation in 2015 and later changed its name from Gritstone Oncology, Inc. to Gritstone bio, Inc. in 2021, reflecting a broader scope beyond oncology alone. Its geographic base has been tied to the California biotech ecosystem, which provides proximity to research talent, venture capital, and partner networks. However, the company also experienced severe financial stress: in October 2024 it filed for Chapter 11 protection in the United States, and in April 2025 it emerged as a leaner organization focused solely on research and development of its oncology technologies.

From a competitive standpoint, Gritstone operates in a crowded and scientifically demanding segment that includes larger immuno-oncology, vaccine, and precision-medicine developers with greater financial resources. Its competitive strengths are its technological focus, niche intellectual property, and ongoing research output, including 2025 patent-related announcements. Its weaknesses are equally clear: limited scale, restructuring history, and dependence on clinical and financing outcomes. As a result, GRTS should be viewed as a high-risk NASDAQ biotechnology name in the United States, tracked less for stable operating cash flow and more for pipeline progress, insider activity reported through Form 4 filings, and corporate restructuring developments.